Loading...
Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
BACKGROUND: Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain. The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in Sp...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3651713/ https://ncbi.nlm.nih.gov/pubmed/23647721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-1991-3-13 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|